Characterizing the subjective, psychomotor, and physiological effects of oral propoxyphene in non-drug-abusing volunteers

Drug and Alcohol Dependence

Volumn 73, Issue 2, 2004, Pages 133-140

  Zacny, James P ^a   Goldman, Rebecca Erin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Abuse liability; Dextropropoxphene; Human; Opioid; Propoxyphene; Subjective

Indexed keywords

DEXTROPROPOXYPHENE NAPSILATE; LORAZEPAM; MORPHINE SULFATE;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITION; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABUSE; DRUG EFFECT; FEMALE; HUMAN; MALE; MEASUREMENT; MIOSIS; NORMAL HUMAN; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 0347318103     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2003.09.007     Document Type: Article

References (54)

1. Ali N.A., Marshall R.W., Allen E.M., Graham D.F., Richens A. Comparison of the effects of therapeutic doses of meptazinol and a dextropropoxyphene/ paracetamol mixture alone and in combination with ethanol on ventilatory function and saccadic eye movements. Br. J. Clin. Pharmacol. 20:1985;631-637.
2. American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders-IV. American Psychiatric Association, Washington, DC.
3. Baddeley A.D. A 3-minute reasoning test based on grammatical transformation. Psychonom. Sci. 10:1968;341-342.
4. Beaver W.T. Mild analgesics: a review of their clinical pharmacology (Part II). Am. J. Med. Sci. 251:1966;576-599.
5. Bigelow G.E. Human drug abuse liability assessment: opioids and analgesics. Br. J. Addict. 86:1991;1615-1624.
6. Carney J.M., Uwaydah I.M., Balster R.L. Evaluation of a suspension system for intravenous self-administration studies of water-insoluble compounds in the rhesus monkey. Pharmacol. Biochem. Behav. 7:1977;357-364.
7. Chapman C.R., Hill H.F., Saeger L., Gavrin J. Profiles of opioid analgesia in humans after intravenous bolus administration: alfentanil, fentanyl and morphine compared on experimental pain. Pain. 43:1990;47-55.
8. Dore G.M. The dangers of dextropropoxyphene. Aust. N. Z. J. Psychiatry. 30:1996;864-866.
9. Ebert B., Andersen S., Hjeds H., Dickenson A.H. Dextropropoxyphene acts as a noncompetitve N-methyl-D-aspartate (NMDA) antagonist. J. Pain Symp. Manage. 15:1998;269-274.
10. Fraser H.F., Isbell H. Pharmacology and addiction liability of dl- and d-propoxyphene. Bull. Narcot. 12:1960;9-14.
11. Fraser H.F., van Horn G.D., Martin W.R., Wolbach A.B., Isbell H. Methods for evaluating addiction liability: (a) "attitude" of opiate addicts toward opiate-like drugs, (b) a short-term "direct" addiction test. J. Pharmacol. Exp. Ther. 133:1961;371-387.
12. Galer B.S., Coyle N., Pasternak G.V., Portenoy R.K. Individual variability in the response to different opioids: report of five cases. Pain. 49:1992;87-91.
13. Gruber C.M. Codeine and propoxyphene in postepisiotomy pain: A two-dose evaluation. J. Am. Med. Assoc. 237:1977;2734-2735.
14. Haertzen C.A. Development of scales based on patterns of drug effects, using the Addiction Research Center Inventory (ARCI). Psychol. Rep. 18:1966;163-194.
15. Hawton K., Simkin S., Deeks J. Co-praxamol and suicide: a study of national mortality statistics and local non-fatal self poisonings. Brit. Med. J. 326:2003;1006-1008.
16. Hayes A.G., Skingle M., Tyers M.B. Evaluation of the receptor selectivities of opioid drugs by investigating the block of their effect on urine output by ß-funaltrexamine. J. Pharmacol. Exp. Ther. 240:1987;984-988.
17. Hoffmeister F. Progressive-ratio performance in the rhesus monkey maintained by opiate infusions. Psychopharmacology. 62:1979;181-186.
18. Hostetler R.M., Reinhard J., Peterson G.R. Model to study long-term effects of propoxyphene napsylate (Darvon-N) on narcotic-dependent mice. Res. Commun. Chem. Pathol. Pharmacol. 15:1976;75-88.
19. Hudson P., Barringer M., McBay A.J. Fatal poisoning with propoxyphene: report from 100 consecutive cases. South. Med. J. 70:1977;938-942.
20. Jasinski D.R., Pevnick J.S., Clark S.C., Griffith J.D. Therapeutic usefulness of propoxyphene napsylate in narcotic addiction. Arch. Gen. Psychiatry. 34:1977;227-233.
21. Jasinski D.R., Preston K.L. Evaluation of tilidine for morphine-like subjective effects and euphoria. Drug Alcohol Depend. 18:1986;273-292.
22. Jonasson U., Jonasson B., Saldeen T. Middle-aged men - a risk category regarding fatal poisoning due to dextropropoxyphene and alcohol in combination. Prevent. Med. 31:2000;103-106.
23. Kiplinger G.F., Sokol G., Rodda B.E. Effect of combined alcohol and propoxyphene on human performance. Arch. Int. Pharmacody. 212:1974;175-180.
24. Martin W.R., Sloan J.W., Sapira J.D., Jasinski D.R. Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin. Pharmacol. Ther. 12:1971;245-258.
25. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., Gilbert P.E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197:1976;517-532.
26. Miksic S., Shearman G., Lal H. Generalization study with some narcotic and nonnarcotic drugs in rats trained for morphine-saline discrimination. Psychopharmacology. 60:1978;103-104.
27. Miller R.R. Propoxyphene: a review. Am. J. Hosp. Pharm. 34:1977;413-423.
28. Mogil J.S. The genetic mediation of individual differences in sensitivity to pain and its inhibition. Proc. Natl. Acad. Sci. U.S.A. 96:1999;7744-7751.
29. Ng B., Alvear M. Dextropropoxyphene addiction - a drug of primary abuse. Am. J. Drug Alcohol Abuse. 19:1993;153-158.
30. Nuotto E.J., Korttila K. Evaluation of a new computerized psychomotor test battery: Effects of alcohol. Pharmacol. Toxicol. 68:1991;360-365.
31. O'Neill W.M., Hanks G.W., White L., Simpson P., Wesnes K. The cognitive and psychomotor effects of opioid analgesics. Part I. A randomized controlled trial of single doses of dextropropoxyphene, lorazepam and placebo in healthy subjects. Eur. J. Clin. Pharmacol. 48:1995;447-453.
32. O'Neill W.M., Hanks G.W., Simpson P., Fallon M.T., Jenkins E., Wesnes K. The cognitive and psychomotor effects of morphine in healthy subjects: a randomized controlled trial of repeated (four) oral doses of dextropropoxyphene, lorazepam and placebo. Pain. 85:2000;209-215.
33. Overton D.A., Batta S.K. Investigation of narcotics and antitussives using drug discrimination techniques. J. Pharmacol. Exp. Ther. 211:1979;401-408.
34. Po A.L.W., Zhang W.Y. Systematic overview of co-praxamol to assess analgesic effects of addition of dextropropoxphene to paracetamol. Br. Med. J. 315:1997;1565-1571.
35. Portenoy R.K., Foley K.M., Inturrisi C.E. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain. 43:1990;273-286.
36. Preston K.L., Bigelow G.E., Bickel W.K., Liebson I.A. Drug discrimination in human postaddicts: Agonist-antagonist opioids. J. Pharmacol. Exp. Ther. 250:1989;184-196.
37. Reisine, T., Pasternak, G., 1996. Opioid analgesics and antagonists. In: Hardman, J.G., Gilman, A.G., Limbird, L.E. (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed. Pergamon Press, New York, pp. 521-555.
38. Rxlist.com., 2003. http://www.rxlist.com/top200.htm . The top 200 prescriptions for 2002 by number of U.S. Prescriptions Dispensed (accessed August 29, 2003).
39. Shannon H.E., Holtzman S.G. Further evaluation of the discriminative effects of morphine in the rat. J. Pharmacol. Exp. Ther. 201:1977;55-66.
40. Soni S.K., van Gelder D. Separation and characterization of standard propoxyphene diastereoisomers and their determination in pharmaceutical preparations. J. Assoc. Off. Anal. Chem. 64:1981;875-883.
41. Substance Abuse and Mental Health Services Administration (SAMHSA), 2002a. Office of Applied Studies, Emergency Department Trends from the Drug Abuse Warning Network, Final Estimates 1994-2001. DAWN Series D-21, DHHS Publication No. (SMA) 02-3635. Rockville, MD, USA.
42. Substance Abuse and Mental Health Services Administration (SAMHSA), 2002b. Office of Applied Studies, Mortality Data From the Drug Abuse Warning Network, 2001. DAWN Series D-23, DHHS Publication No. (SMA) 03-3781. Rockville, MD, USA.
43. Sturrock R.D. Efficacy: UK experience. Human Toxicol. 3:1984;221S-227S.
44. Sunshine A., Laska E., Slafta J., Fleischman E. A comparative analgesia study of propoxyphene hydrochloride, propoxyphene napsylate, and placebo. Toxicol. Appl. Pharmacol. 19:1971;512-518.
45. Walker E.A., Tiano M.J., Benyas S.I., Dykstra L.A., Picker M.J. Naltrexone and ß-funaltrexamine antagonism of the antinociceptive and response-rate decreasing effects of morphine, dezocine, and d-propoxyphene. Psychopharmacology. 144:1999;45-53.
46. Walker D.J., Zacny J.P. Subjective, psychomotor, and analgesic effects of oral codeine and morphine in healthy volunteers. Psychopharmacology. 140:1998;191-201.
47. Walker D.J., Zacny J.P. Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers. J. Pharmacol. Exp. Ther. 289:1999;1454-1464.
48. Wechsler, D., 1958. The Measurement and Appraisal of Adult Intelligence. Williams and Wilkins, Baltimore, MD, USA.
49. Weinhold L.L., Bigelow G.E. Opioid miosis: effects of lighting intensity and monocular and binocular exposure. Drug Alcohol Depend. 31:1993;177-181.
50. Wetli C.V., Badnarczyk L.R. Deaths related to propoxyphene overdose: a ten year assessment. South Med. J. 73:1980;1205-1209.
51. Young R.J. Dextropropoxyphene overdosage. Drugs. 26:1983;70-79.
52. Young A.M., Swain H.M., Woods J.H. Comparison of opioid agonists in maintaining responding and in suppressing morphine withdrawal in rhesus monkeys. Psychopharmacology. 74:1981;329-335.
53. Zacny J.P. Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers. Psychopharmacology. 165:2003;146-156.
54. Zacny J.P., Gutierrez S. Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharmacology. 170:2003;242-254.